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Ablation of Symptomatic Cysts 
Using Absolute Ethanol in 11 Patients
with Autosomal-Dominant Polycystic
Kidney Disease
Objective: To evaluate the effects of cyst ablation with absolute ethanol in
autosomal-dominant polycystic kidney disease (ADPKD) patients with sympto-
matic cysts.
Materials and Methods: Using absolute ethanol, cyst ablation was performed
in 11 patients with documented ADPKD who suffered cyst pain refractory to med-
ical treatment. An ethanol solution was instilled into the largest symptomatic cysts
through a catheter. We assessed the therapeutic efficacy of the procedure by
tracking subjective pain relief during a 3 to 24-month follow-up period after abla-
tion.
Results: At follow-up, we found that the duration of subjective pain relief was
12 to 24 months in seven patients, 4 to11 months in one, and less than 3 months
in three.
Conclusion: Selective ablation of a symptomatic cyst may be a valid option in
managing chronic pain caused by one or a few large cysts in ADPKD patients.
t is well known that the progressive enlargement of renal cysts in autoso-
mal- dominant polycystic kidney disease (ADPKD) patients is frequently
associated with abdominal pain, which afflicts about 60% of patients (1).
When medical analgesics fail to alleviate the pain, cyst decompression procedures, in-
cluding surgical intervention, may be necessary (1 4). 
Although the ablation of simple cysts has proved effective, the use of this procedure
for symptomatic patients with ADPKD has only recently been investigated (5 7).
Percutaneous sclerotherapy may be difficult in ADPKD, due to the presence of multi-
ple cysts and the difficulty in identifying those which cause pain, selective ablation is,
however, effective for the management of chronic pain caused by one or a few large
cysts (5, 6).
The purpose of this study was to evaluate the effects of cyst sclerotherapy with ab-
solute ethanol in ADPKD patients with symptomatic large cyst(s).
MATERIALS AND METHODS
Eleven patients with ADPKD [M:F = 6:5; age, 20 73 (average, 41.8) years] were in-
volved in this study. All complained of abdominal or flank pain caused by enlarged
cysts, but none required pain-relieving surgery. Four had hypertension, and two com-
plained of a palpable abdominal mass. A patient with a large and painful cyst who did
not respond to medical treatment was considered a candidate for cyst sclerotherapy.
To localize the pain, we reviewed a patient’s detailed clinical history and decided to
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Itarget the largest cysts, as determined by radiological imag-
ing (US and/or CT). The procedure was restricted to pa-
tients who had severe pain attributed to cysts greater than
5 cm in diameter. In all cases, informed consent was ob-
tained. 
All procedures were performed on an in-patient basis.
The patient was placed either in a prone or recumbent po-
sition after confirming the location of the largest cyst using
US. After sterile preparation, a 22-gauge puncture needle
was inserted into the cyst under ultrasonographic (US)
guidance. It was then removed, and replaced by a 6-F pig-
tail catheter, inserted over the guidewire. To determine the
existence of any connection with the collecting system and
to test for the extravasation of cystic fluid, contrast medi-
um was injected (Fig. 1), and to permit natural drainage,
the catheter was left open. Absolute ethanol (99.8%: J.T.
Baker, Holland) was used as the sclerosing agent. On the
following day, after completely draining the cystic fluid
and ascertaining its volume, we instilled an amount of scle-
rosing agent equal to one quarter of the volume of the
drained fluid. The cystic volume was calculated using the
formula: anterior-posterior diameter transverse diameter
length 0.523 cc. During this period, the patient was in-
structed to lie in the supine, prone, and left and right later-
al positions successively to facilitate adequate exposure of
the cyst wall to the sclerosing agent. The ethanol was then
aspirated, and the catheter was left in place for the next
treatment session, performed on the following day. The
pigtail catheter was removed after completely draining all
fluid. 
The mean follow-up period was 12 (range, 3 to 24)
months. In five patients, follow-up CT studies were per-
formed at 9 15 (mean, 11.6) months. Therapeutic efficacy
was assessed on the basis of the patients’ subjective judg-
ment of their symptoms (abdominal and/or flank pain) dur-
ing their most recent follow-up visit. Blood pressure was
also checked, and any changes were recorded.
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Fig. 1. ADPKD in a 34-year-old man. 
A. Axial contrast enhanced CT scan depicts multiple cysts in both
kidneys. An 8-cm cyst, present in the left kidney (arrows) was ablat-
ed. 
B. Sinogram obtained during sclerotherapy shows no evidence of
extravasation or connection with the collecting system. 
C. Twelve-month follow-up CT reveals no evidence of re-expansion
of the treated cyst. Pain was relieved for 18 months. 
A
C
BRESULTS
Each patient was treated for the largest cyst on the symp-
tomatic side, and all tolerated the procedure very well. Six
of the cysts were on the right side, and four were on the
left; in one case, cysts were present bilaterally (Fig. 2). In
all patients, the punctured cysts were 5 10 (mean, 7.3) cm
in diameter. The average volume of the sclerosing agent
was 30 (range 15 100) cc, and the catheter was kept in
place 2 to 5 (mean, 2.9) days. Sclerotherapy gave rise to
complications in five patients. Four experienced pain, that
was treated conservatively, and one suffered mild and
transient gross hematuria.
At follow-up, we found that the duration of subjective
pain relief was 12 to 24 months in seven patients, 4 to11
months in one, and less than 3 months in three. After the
procedure, one of four patients with hypertension became
normotensive, and in two with a palpable mass, symptoms
improved.
DISCUSSION
ADPKD is characterized by progressively enlarging cysts
associated with hypertension, renal failure, pain, hematuria
and infection (2). Abdominal discomfort or lumbago is one
of the most frequent, as well as difficult to manage, compli-
cations of the condition. The acute onset of pain is often at-
tributed to a ruptured cyst or blood vessel, with extravasa-
tion of cystic fluid or blood into perinephric tissues (3).
Chronic pain syndrome is well documented in ADPKD
patients with large cysts and/or much-enlarged kidneys (3,
8). The impression that severe pain occurs under these cir-
cumstances is supported by the observation made by
Elzinga et al. that 80% of patients who had experienced
pain were pain-free one year after surgical decompression
of their cysts (9). Pain occurs due to compression by sur-
rounding tissues, traction on the pedicle of the kidney, and
distension of the renal capsule. The severity of pain gener-
ally correlates with the size of the kidneys, but there are
some exceptions. Pain related directly to cyst formation
tends to be steady and nagging discomfort, exacerbated by
standing and walking. Patients can frequently localize the
source of pain with one finger, anterior abdominal being
more common than localized back pain. A detailed history
focusing on pain location and duration, and associated
symptoms and maneuvers to produce relief, will frequently
distinguish pain related directly to cyst formation from me-
chanical back pain due to changes in posture caused by en-
larging cysts (1). For this reason we obtained a detailed
clinical history and decided to target the largest cysts de-
picted at radiological imaging (US and/or CT).
When medical analgesics fail to relieve intolerable pain,
cyst decompression procedures can be effective (10). An
early technique employed was percutaneous aspiration of
the cysts under ultrasonographic guidance (11). Simple cyst
aspiration can relieve pain temporarily, supporting the hy-
pothesis that cyst distention can cause pain (10), but aspira-
tion alone is inefficient because cysts will reaccumulate flu-
id due to an active chloride transport process (1). Thus,
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Fig. 2. ADPKD in a 52-year-old woman. 
A. Axial contrast-enhanced CT scan obtained prior to sclerotherapy depicts symptomatic cysts in both kidneys (arrows). Cyst ablation
was performed bilaterally. 
B. Follow-up CT at 18 months shows reduced renal volume and no evidence of cyst re-expansion. Pain relief lasted 18 months.
ABcyst contraction involving the use of a sclerosing agent
may be more effective in lessening the symptoms associat-
ed with simple renal cysts as well as those occurring in
ADPKD. For treating extremely large kidneys with multi-
ple large cysts, cyst decortication and even nephrectomy
have been effectively performed using laparoscopic tech-
niques (12).
Percutaneous sclerotherapy is an effective method for
treating benign renal cysts (13 15). Several agents have
been used to destroy the cyst wall epithelium, including
ethanol (13 16), minocycline hydrochloride (6, 7), povi-
done-iodine (17), acetic acid (18), and ethanolamine oleate
(19); of these various sclerosants, absolute ethanol was
used in the present study. This rapidly inactivates the se-
creting cells of the cysts, and because it is very slow to pen-
etrate the fibrous cystic capsule, can be removed before
the renal parenchyma is affected (14). Seo et al., however,
found that in patients treated with large amounts, its sys-
temic absorption led to fever and a drunken state (18).
Because the volume of the sclerosing agent used was about
one quarter that of the cystic volume, there were no such
cases in the present study; mild pain and transient hema-
turia were the only complications. Recurrence after alcohol
sclerotherapy was reported by Seo et al. in over 30% of
cases (18), and was probably caused by incomplete abla-
tion of the cystic wall due to dilution by the fluid remain-
ing in the cyst (2). Repeated injections of sclerosing agent
have led to substantially decreased rates of recurrence (14,
20). Thus, in order to facilitate multiple treatment sessions,
we routinely inserted a catheter into a cyst. A small- cal-
iber pigtail catheter was used, and there was no damage to
the collecting system or adjacent organs. Thus, sclerothera-
py is a safe procedure, and the reaccumulation of cystic flu-
id is reduced by the repeated instillation of a sclerosing
agent through the catheter. 
However, the application of this ablation technique is not
easy in symptomatic ADPKD patients with many cysts into
which catheters should be inserted. Kim et al. (5) recently
reported that percutaneous needle aspiration and the intra-
cystic injection of a mixture of n-butyl cyanoacrylate with
iodized oil, performed during the same treatment session,
is effective for the ablation of multiple renal cysts.
Our results showed that the percentage probability of be-
ing pain free one year after sclerotherapy was 64%. Thus,
the selective ablation of symptomatic cysts present in
ADPKD patients should be considered a valid option in
managing chronic pain caused by one or more large cysts.
To assess the long-term effects of these procedures on
the outcome of ADPKD in terms of the duration of pain
relief, further study and follow-up is needed.
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